

GRAZIE AL TUO IMPEGNO LE LORO STORIE CONTINUANO



Xarelto® nei pazienti con Tromboembolismo Venoso e Cancro

Il programma di studi OSCAR include pazienti con TEV e cancro in accordo alle più recenti LG in cardioncologia (ESC 2022).

OSCAR-US

OSCAR-UK


OSCAR-SWE

OSCAR meta-analysis*²




Patients with CAT[†] treated with Xarelto® (n=1690) or LMWH (n=9741)

Recurrent VTE



Major bleeding



With reassuring real-world outcomes, you can protect what matters for your vulnerable patients with Xarelto®²

CAT, cancer-associated thrombosis; **CI**, confidence interval; **CNS**, central nervous system; **HR**, hazard ratio; **ISTH**, International Society on Thrombosis and Haemostasis; **LMWH**, low-molecular-weight heparin; **NOAC**, non-vitamin K antagonist oral anticoagulant; **RRR**, relative risk reduction; **SWE**, Sweden; **VTE**, venous thromboembolism.

* Meta-analysis of three real-world observational studies including OSCAR-US (Optum Electronic Health Records dataset, 2013–2020), OSCAR-UK (Clinical Practice Research Datalink, 2013–2020) and OSCAR-SWE (Swedish Cancer Register, 2013–2020); 1690 Xarelto® (range=283–1093) and 9741 LMWH patients (range=1945–5181) were included in the meta-analysis; no significant heterogeneities in effect sizes were observed between studies (I² statistic=0 for all). Eligible patients had CAT[†] and received Xarelto or LMWH. Primary efficacy outcome was recurrent VTE at 3 and 6 months. Primary safety outcome was major bleeding, defined as fatal bleeding or bleeding-related hospitalisation, at 3 and 6 months.²

[†] Endorsed for NOAC use in the ISTH guidelines,³ excluding those with oesophageal, gastric, unresected colorectal, bladder, CNS cancers other than the brain, and leukaemia.²

[‡] RRR calculated as 1-HR

1. Bayer AG. IQVIA MIDAS, Database Quarterly Sales Q4 2022. Bayer estimate based on calculations on IQVIA data; 2. Coleman CI, Caroti KS, Abdelgawwad K et al. Effectiveness and safety of rivaroxaban and low molecular weight heparin in cancer-associated venous thromboembolism: a meta-analysis of the OSCAR programme findings. International Society on Thrombosis and Haemostasis (ISTH). Montréal, Canada, 24–28 June 2023. Oral presentation 54.1; 3. Khorana AA, Noble S, Lee AYY et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16:1891–1894